SCHEMBL11980474

SCHEMBL11980474

CC(=O)N1CCCC(CCBr)C1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.38
CYP4A11 Q02928 2/20 0.38
FEN1 P39748 1/20 0.38
BRD4 O60885 6/20 0.37
ALDH1A1 P00352 2/20 0.37
LMNA P02545 1/20 0.37
NPC1 O15118 1/20 0.36
POLB P06746 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CHRNB2 P17787 1/20 0.36
CHRNA3 P32297 1/20 0.36
CHRNA4 P43681 1/20 0.36
CHRNB3 Q05901 1/20 0.36
CHRNA6 Q15825 1/20 0.36
EPHX2 P34913 1/20 0.35
MAPK1 P28482 1/20 0.35
AKR1C3 P42330 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21049974 0.86 CYP4F2 (0.39) CYP4F2CYP4A11FEN1BRD4ALDH1A1
SCHEMBL22968160 0.84 AKR1C3 (0.47) CYP4F2CYP4A11FEN1BRD4ALDH1A1
SCHEMBL2347493 0.84 AKR1C3 (0.36) ALDH1A1LMNANPC1POLBRAB9A
SCHEMBL19277073 0.84 AKR1C3 (0.47) CYP4F2CYP4A11FEN1BRD4ALDH1A1
SCHEMBL4494838 0.84 POLB (0.41) CYP4F2CYP4A11FEN1BRD4ALDH1A1
SCHEMBL14393689 0.84 AKR1C3 (0.47) CYP4F2CYP4A11FEN1BRD4ALDH1A1
SCHEMBL3241046 0.83 ALDH1A1 (0.44) CYP4F2CYP4A11FEN1BRD4ALDH1A1
SCHEMBL12683452 0.80 CYP4F2 (0.40) CYP4F2CYP4A11FEN1BRD4ALDH1A1
SCHEMBL20942599 0.80 RAB9A (0.51) CYP4F2CYP4A11FEN1ALDH1A1NPC1
SCHEMBL21665823 0.80 RAB9A (0.51) CYP4F2CYP4A11FEN1ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160310497-A1 PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH 2016-10-27 US disclosed
US-9328114-B2 Hsp90 inhibitors SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2016-05-03 US disclosed
US-20120208806-A1 Hsp90 Inhibitors SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2012-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120208806-A1 Hsp90 Inhibitors HSP90B1, HSP90AB1, HSP90AB2P CYP4F2 4127/4885CYP4A11 4385/4885FEN1 3741/4885
US-20160310497-A1 PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS XDH, HSP90B1, HSP90AA1 CYP4F2 1625/4885CYP4A11 1914/4885FEN1 2116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.